Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Spero Therapeutics (SPRO) Accumulated Depreciation & Amortization (2016 - 2024)

Spero Therapeutics' Accumulated Depreciation & Amortization history spans 9 years, with the latest figure at $3.6 million for Q4 2024.

  • For Q4 2024, Accumulated Depreciation & Amortization changed 0.06% year-over-year to $3.6 million; the TTM value through Dec 2024 reached $3.6 million, changed 0.06%, while the annual FY2024 figure was $3.6 million, 0.06% changed from the prior year.
  • Accumulated Depreciation & Amortization reached $3.6 million in Q4 2024 per SPRO's latest filing, roughly flat from $3.6 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $3.6 million in Q4 2024 to a low of $2.3 million in Q4 2020.
  • Average Accumulated Depreciation & Amortization over 5 years is $3.1 million, with a median of $3.3 million recorded in 2022.
  • Peak YoY movement for Accumulated Depreciation & Amortization: skyrocketed 50.23% in 2020, then increased 0.06% in 2024.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $2.3 million in 2020, then grew by 26.54% to $2.9 million in 2021, then rose by 12.92% to $3.3 million in 2022, then rose by 11.25% to $3.6 million in 2023, then increased by 0.06% to $3.6 million in 2024.
  • Per Business Quant, the three most recent readings for SPRO's Accumulated Depreciation & Amortization are $3.6 million (Q4 2024), $3.6 million (Q4 2023), and $3.3 million (Q4 2022).